Right Turn: Primer on MSCs in clinical trials

Author: Stacey Johnson, 04/19/13

.
In this podcast titled “Opportunities and Challenges in Developing Innovative Stem Cell Therapies,” Dr. Armand Keating focuses specifically on the commercialization of mesenchymal stem cells (stromal cells). He has established the largest stem cell transplant program in Canada and his clinical and research interests focus on anti-cancer cell therapy, blood and marrow transplantation, leukemia, lymphoma and cell-based tissue regeneration. Dr. Keating is the Epstein Chair in Cell Therapy and Transplantation, University of Toronto, and Director of the Cell Therapy Program at the Princess Margaret Hospital, University Health Network (Toronto).

Click to hear podcast: Opportunities and Challenges in Developing Innovative Stem Cell Therapies

 

Our regular feature, Right Turn, showcases the “lighter” side of stem cells and regenerative medicine. Every Friday, we will bring you cartoons, photos, videos and other content that may be just as thought provoking as the written submissions that you are used to finding here, but they definitely won’t be blogs.

As always, we welcome your feedback and we also welcome suitable submissions. Be creative! Use the right (!) side of your brain. Make us laugh! Let’s see if we can make this new direction a positive one for all of us. Send your submission to info(at)ccrm.ca.

The following two tabs change content below.
Stacey Johnson

Stacey Johnson

For almost 20 years, Stacey has been providing strategic communications counsel to government, corporate, technology and health organizations. Prior to that, Stacey was at the CTV Television Network, first as a researcher, then as a story producer for “Goldhawk Fights Back,” a special ombudsman segment that aired weekly on the National News and Canada AM. Before joining CCRM as the Director, Communications and Marketing, Stacey was the Director of Communications for the Canadian Arthritis Network. Stacey is editor of Signals. You can follow Stacey on Twitter @msstaceyerin.
Tags: , , , ,

One Response

Leave a Reply

*
*